Seer, Inc. (SEER) Q2 2026 Filing Summary
Business Context and Reporting Period
This summary covers Seer, Inc.'s Quarterly Report on Form 10-Q for the period ended June 30, 2026. Seer is a life sciences technology company focused on the Proteograph Product Suite, which utilizes proprietary engineered nanoparticle technology for deep proteomic analysis. The company is classified as a smaller reporting company and a non-accelerated filer.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $3.1 million | $4.1 million | $5.9 million | $8.3 million |
| Gross Profit | $1.5 million | $2.1 million | $2.5 million | $4.2 million |
| Gross Margin | 48.6% | 52.1% | 42.2% | 50.5% |
| Net Loss | $(16.9) million | $(19.4) million | $(33.7) million | $(39.4) million |
| Loss Per Share (Diluted) | $(0.31) | $(0.33) | $(0.61) | $(0.67) |
| Operating Cash Flow | N/A | N/A | $(25.0) million | $(26.1) million |
| Cash & Investments | $209.5 million (as of June 30, 2026) | |||
| Accumulated Deficit | $(499.7) million (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 23% year-over-year in Q2 2026 and 29% year-over-year for the six-month period. This was driven by lower product sales and service revenue.
- Expense Reduction: Operating expenses decreased significantly. Research and Development (R&D) expenses fell 32% in Q2 and 27% YTD, primarily due to lower employee compensation and stock-based compensation. Selling, General, and Administrative (SG&A) expenses decreased 5% in Q2 and 11% YTD.
- Improved Loss Profile: Despite revenue declines, the net loss narrowed by 13% in Q2 and 14% YTD compared to the prior year periods, reflecting the successful reduction in operating costs.
- Investment Activity: The company recognized a loss on its equity method investment in PrognomiQ, Inc., which increased slightly year-over-year. Interest income decreased due to lower rates on cash equivalents and investments.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash, cash equivalents, and investments ($209.5 million) are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring operating losses in the near term.
- Commercialization: The company is focused on broadening the adoption of the Proteograph Product Suite, expanding its installed base, and increasing utilization of consumables. International revenue accounted for 57% of total revenue in Q2 2026.
- Share Repurchases: The Board authorized an additional $25.0 million share repurchase program in February 2026. As of June 30, 2026, approximately $25.1 million remains available for future repurchases.
- Intellectual Property Litigation: Seer filed patent infringement lawsuits against Nanomics Biotechnology Co., Ltd. in the Northern District of Illinois and with the U.S. International Trade Commission (ITC) in May 2026. The ITC investigation was instituted in June 2026, and the federal lawsuit was stayed pending the ITC outcome.
- Risk Factors: Key risks include the company's history of losses, dependence on the Proteograph Product Suite for revenue, reliance on a single contract manufacturer (Hamilton Company) for instruments, and potential limitations on the use of Net Operating Losses (NOLs) due to ownership changes.
Investor Verification Checklist
- Revenue Trajectory: Verify the sustainability of the revenue decline and the timeline for expected growth from the new Proteograph ONE assay and SP200 instrument.
- Cost Structure: Assess whether the significant reduction in R&D and SG&A expenses impacts the company's ability to innovate or scale commercial operations.
- IP Litigation Status: Monitor the progress of the ITC investigation and federal lawsuit against Nanomics, as outcomes could materially affect competitive positioning.
- Supplier Concentration: Evaluate the risks associated with reliance on Hamilton Company for instrument manufacturing and the availability of alternative suppliers.
- Cash Burn Rate: Confirm the runway provided by the $209.5 million in liquid assets against the current quarterly cash burn rate of approximately $12.5 million (based on YTD operating cash flow).